Urmăriți
salman fazal
salman fazal
Afiliere necunoscută
Adresă de e-mail confirmată pe AHN.ORG
Titlu
Citat de
Citat de
Anul
Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease
R Zeiser, N Polverelli, R Ram, SK Hashmi, R Chakraverty, JM Middeke, ...
New England Journal of Medicine 385 (3), 228-238, 2021
4042021
Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial
M Jagasia, MA Perales, MA Schroeder, H Ali, NN Shah, YB Chen, S Fazal, ...
Blood, The Journal of the American Society of Hematology 135 (20), 1739-1749, 2020
2702020
Myeloproliferative neoplasms (MPNs) have a significant impact on patients’ overall health and productivity: the MPN Landmark survey
R Mesa, CB Miller, M Thyne, J Mangan, S Goldberger, S Fazal, X Ma, ...
BMC cancer 16, 1-10, 2016
1992016
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study
S Verstovsek, AT Gerds, AM Vannucchi, HK Al-Ali, D Lavie, ...
The Lancet 401 (10373), 269-280, 2023
1462023
Supportive and palliative care of pancreatic cancer
S Fazal, MW Saif
Jop 8 (2), 240-253, 2007
1092007
Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists/oncologists in the United States …
RA Mesa, CB Miller, M Thyne, J Mangan, S Goldberger, S Fazal, X Ma, ...
Cancer 123 (3), 449-458, 2017
822017
Pharmacokinetic exposure equivalence and preliminary efficacy and safety from a randomized cross over phase 3 study (ASCERTAIN study) of an oral hypomethylating agent ASTX727 …
G Garcia-Manero, J McCloskey, EA Griffiths, KWL Yee, AM Zeidan, ...
Blood 134, 846, 2019
722019
Azacitidine in the management of patients with myelodysplastic syndromes
C Khan, N Pathe, S Fazal, J Lister, JM Rossetti
Therapeutic advances in hematology 3 (6), 355-373, 2012
722012
Successful plasma exchange combined with rituximab therapy in aggressive APS-related cutaneous necrosis
R Costa, S Fazal, RB Kaplan, J Spero, R Costa
Clinical rheumatology 32, 79-82, 2013
452013
Polycythemia
AA Pillai, S Fazal, SKR Mukkamalla, HM Babiker
382018
Myeloproliferative neoplasms
B Thapa, S Fazal, M Parsi, HJ Rogers
262018
Oral decitabine–cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised …
G Garcia-Manero, J McCloskey, EA Griffiths, KWL Yee, AM Zeidan, ...
The Lancet Haematology 11 (1), e15-e26, 2024
222024
Clinical efficacy and safety of oral decitabine/cedazuridine in 133 patients with myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML)
MR Savona, JK McCloskey, EA Griffiths, KWL Yee, A Al-Kali, AM Zeidan, ...
Blood 136, 37-38, 2020
222020
Tagraxofusp followed by combined azacitidine and venetoclax in blastic plasmacytoid dendritic cell neoplasm: a case report and literature review
Y Samhouri, S Ursu, N Dutton, V Tanvi, S Fazal
Journal of Oncology Pharmacy Practice 27 (4), 990-995, 2021
212021
A case of autoimmune haemolytic anaemia after 39 cycles of nivolumab
H Shaikh, N Daboul, M Albrethsen, S Fazal
Case Reports 2018, bcr-2018-224608, 2018
182018
Impact of myeloproliferative neoplasms (MPNs) on patients’ overall health and productivity: results from the MPN LANDMARK SURVEY in the United States
R Mesa, CB Miller, M Thyne, J Mangan, S Goldberger, S Fazal, X Ma, ...
Blood 124 (21), 3183, 2014
182014
Efficacy and tolerability of treatment with azacitidine for 5 days in elderly patients with acute myeloid leukemia
SK Sadashiv, C Hilton, C Khan, JM Rossetti, HL Benjamin, S Fazal, ...
Cancer medicine 3 (6), 1570-1578, 2014
172014
Cerebral aspergillosis in a patient on ibrutinib therapy—A predisposition not to overlook
MS Faisal, H Shaikh, A Khattab, M Albrethsen, S Fazal
Journal of Oncology Pharmacy Practice 25 (6), 1486-1490, 2019
152019
Rituximab-induced acute severe thrombocytopenia: a case series in patients with mantle cell lymphoma
SK Sadashiv, R Rao, S Fazal, J Lister
Clinical Lymphoma Myeloma and Leukemia 13 (5), 602-605, 2013
152013
Safety and efficacy of fedratinib in patients with Primary (P), Post-Polycythemia Vera (Post-PV), and Post-Essential Thrombocythemia (Post-ET) Myelofibrosis (MF) previously …
V Gupta, A Yacoub, S Verstovsek, R Mesa, C Harrison, AM Vannucchi, ...
Blood 140 (Supplement 1), 3935-3937, 2022
132022
Sistemul nu poate realiza operația în acest moment. Încercați din nou mai târziu.
Articole 1–20